// App-Quantinova.ai

415 : Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH): Impact on Health-Related Quality of Life

Researchers

Presenter

  • W. A. Wuyts

Principal Investigators

  • S. D. Nathan

  • A. U. Wells

  • S. A. Harari

  • K. Samara

  • M. Bengus

  • F. Gilberg

  • J. Behr

Medical Centers

  • Department of Pulmonary Medicine, Unit for Interstitial Lung Diseases, University of Leuven, Leuven, Belgium

  • Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom

  • Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, United States

  • Department of Medicine, Ospedale San Giuseppe, Milan, Italy

  • Department of Internal Medicine V, University of Munich, Munchen, Germany

Locations

  • Belgium

  • United Kingdom

  • Switzerland

  • United States

  • Italy

  • Germany

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Pulmonary arterial hypertension

  • Pulmonary fibrosis

  • Hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Pirfenidone

  • Sildenafil citrate

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02951429

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved